Factor VIII and methods of preparation of its concentrates
| Autor: | N. O. Shurko, M. I. Voroniak, T. V. Danysh |
|---|---|
| Jazyk: | English<br />Ukrainian |
| Rok vydání: | 2014 |
| Předmět: | |
| Zdroj: | Біологічні студії, Vol 8, Iss 1, Pp 197-204 (2014) |
| Druh dokumentu: | article |
| ISSN: | 1996-4536 2311-0783 |
| DOI: | 10.30970/sbi.0801.330 |
| Popis: | To correct factor deficiency or prevent bleeding in patients with hemophilia A, the replacement therapy is carried out. This therapy involves administrating plasma or recombinant preparations of factor VIII. A variety of plasma- and recombinant-derived factor preparations are used for haemophilia treatment in Ukraine. Depending on purification level, the following types of plasma-derived concentrates are defined: intermediate purity products obtained through classic techniques of precipitation/adsorption, and high-purity concentrates purified through ion exchange or affinity chromatography. Since the late 1980s, recombinant factor drugs were brought into use in medical practice. They are synthesised by a genetically engineered Chinese hamster ovary cell line or baby hamster kidney. Recombinant factors are classified in generations according to the additional content of impurity human or animal proteins in a final product. The article provides an analysis of the main plasma-derived and recombinant factor VIII preparations registered in Ukraine. Basic properties, methods of preparation and methods of viral inactivation are described. The advantages and disadvantages of plasma-derived and recombinant products are generalized. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|